There are 2789 resources available
674P - WITNESS: Real-world outcomes of patients (pts) with advanced renal cell carcinoma (aRCC) treated with nivolumab in France and subgroup analysis of patients receiving concomitant medications at baseline
Presenter: Antoine Thiery-Vuillemin
Session: ePoster Display
675P - Changes in treatment patterns and survival in renal cell carcinoma (RCC) patients in Norway: A nationwide registry study for 1995-2018
Presenter: Katarina Puco
Session: ePoster Display
697P - Impact of β-blockers (BB) on outcomes of metastatic renal cell carcinoma (mRCC) patients treated with nivolumab (N)
Presenter: Carolina Alves Costa Silva
Session: ePoster Display
677P - Immunotherapy vs sunitinib as first-line treatment for advanced renal cell carcinoma in favourable risk patients: A meta-analysis of randomized clinical trials
Presenter: Ray Manneh Kopp
Session: ePoster Display
678P - Cytoreductive nephrectomy (CN) for patients with metastatic sarcomatoid and/or rhabdoid (S/R) renal cell carcinoma (RCC) treated with immune checkpoint inhibitors (ICI)
Presenter: Andrew Hahn
Session: ePoster Display
680P - Cabozantinib and axitinib after VEGF therapy in patients with aRCC: A retrospective cohort study
Presenter: Janet Brown
Session: ePoster Display
681P - Real-world (RW) clinical outcomes for metastatic renal cell carcinoma (mRCC)
Presenter: Saby George
Session: ePoster Display
682P - Real-world utilization and outcomes of immune-based combination therapies or tyrosine kinase inhibitors (TKIs) for advanced renal cell carcinoma (aRCC)
Presenter: Daniel Geynisman
Session: ePoster Display
683P - Impact of renin-angiotensin system inhibitors (RASi) on outcomes in patients with metastatic renal cell carcinoma (mRCC) treated with immune checkpoint inhibitors (ICI)
Presenter: Pier Vitale Nuzzo
Session: ePoster Display